Stryker Completes Acquisition of NICO Corporation

This acquisition further strengthens Stryker's commitment to neurotechnology through tumor and stroke care.

ICH, or bleeding in the brain caused by a ruptured blood vessel, is the deadliest form of stroke, affecting over 3.4 million people annually around the world, with rising rates due to an aging population. ICH has high morbidity and a 30-day mortality rate ranging from 40-50%. NICO's BrainPath and Myriad products enable a treatment option for ICH with improved functional outcomes compared to guideline-based medical management alone, the current standard of care.

"The acquisition of NICO Corporation expands Stryker's portfolio of solutions for tumor resection and the treatment of intracerebral hemorrhage, the deadliest form of stroke," said Andy Pierce, group president, MedSurg and Neurotechnology, Stryker. "As a global leader in neurosurgical access and removal tools, this strategic addition enables us to deliver differentiated, minimally invasive approaches that will drive meaningful outcomes and improve the lives of patients worldwide."

Related Links:
Stryker
NICO Corporation